RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular, diabetology, orthopedics, neuropsychiatry, respiratory, nutritional, general, urology, anti-diabetic, anti-dengue, vitamins and minerals, gynecology and pediatrics, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
P/E ratio for RPG Life Sciences Limited (RPGLIFE.NS)
P/E ratio as of 2023: 29.11
According to RPG Life Sciences Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 29.11. At the end of 2022 the company had a P/E ratio of 17.13.
P/E ratio history for RPG Life Sciences Limited from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 29.11 |
| 2022 | 17.13 |
| 2021 | 18.01 |
| 2020 | 16.02 |
| 2019 | 9.68 |
| 2018 | 39.62 |
| 2017 | 48.84 |
| 2016 | 36.25 |
| 2015 | 31.56 |
| 2014 | 273.34 |
| 2013 | 1.86 |
| 2012 | 22.50 |
| 2011 | 124.50 |
| 2010 | 9.93 |
| 2009 | 9.72 |
| 2008 | 5.03 |
| 2007 | 7.89 |
| 2006 | 16.09 |